LM103 (tumor-infiltrating lymphocytes) as adjuvant treatment after surgery for non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized Phase IIa trial will enroll 36 to 45 patients who received neoadjuvant PD‑1 antibody therapy and underwent complete resection for resectable non‑small cell lung cancer. Participants will be randomly assigned 1:1:1 to two different LM103 (TILs) experimental groups or a control group and followed for 24 to 36 months. Key eligibility includes age 18–75, ECOG 0–1, negative actionable driver mutations, no post‑surgery recurrence, and adequate organ function. The primary approach is to deliver LM103 as adjuvant cellular immunotherapy in the post‑operative setting to see if it reduces recurrence risk compared with control.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At the date of signing Informed Consent Form (ICF), 18 \~75 years old, male or female;
* Expected survival time \>3 months;
* ECOG performance status 0-1;
* Pathologically diagnosed as resectable non-small cell lung cancer:

  1. Received preoperative neoadjuvant therapy (including PD-1 antibody);
  2. Screening criteria:

  i. Driver gene mutations was negative; ii. No disease recurrence (including local recurrence) after surgery; iii. Expected to complete standard adjuvant therapy.
* Patients have lesions that can be used for surgical resection or biopsy puncture;
* Patients have sufficient hematology and organ functions;
* Voluntarily sign a written informed consent form (ICF).

Exclusion Criteria:

* A history of other malignant tumors within the past 5 years, excluding malignant tumors that can be expected to heal after treatment (including but not limited to well-treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery);
* Adverse reactions caused by previous treatments have not been recovered to grade ≤1 (CTCAE V6.0) (excluding alopecia and neurotoxicity, and hypothyroidism, adrenal insufficiency and hypopituitarism that cannot be restored to grade 2 as determined by the investigators for a long time);
* Any immune-related adverse reaction (irAE) with a severity level greater than grade 3 that has occurred during any previous immunotherapy and has been permanently discontinued;
* Have received vaccination within two months prior to signing the ICF, or plan to receive vaccination during the study;
* Have received TIL cell therapy, allogeneic T cell therapy or NK cell therapy within 6 months prior to signing the ICF;
* Have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation in the past;
* Suffering from or suspected of having an active autoimmune disease;
* Suffering from a large amount of pleural effusion or ascites with clinical symptoms or requiring symptomatic treatment;
* Patients with current or previous irreversible interstitial lung disease;
* Suffering from serious cardiovascular and cerebrovascular diseases;
* Suffering from an active infection that requires systemic treatment;
* Suffering from infectious diseases such as hepatitis B, hepatitis C, syphilis, AIDS;
* Patients with esophageal or gastric varices requiring immediate intervention (such as ligation or sclerotherapy), or those with a higher risk of bleeding as recommended by the investigator or gastroenterologist or hepatologist, evidence of portal hypertension (including splenomegaly found in imaging examinations), or a history of variceal bleeding must undergo endoscopic assessment within 3 months before enrollment;
* Uncontrolled metabolic disorders, such as diabetes, or other non-malignant organ or systemic diseases or secondary reactions to cancer, can lead to higher medical risks and/or uncertainties in survival assessment;
* Those who are known to be allergic to any component of the investigational drug and the LM103 product formula;
* Women who are pregnant or breastfeeding;
* As determined by the investigators, there are other severe, acute or chronic medical diseases, mental disorders or laboratory abnormalities that may increase the risks related to participation in the study or may interfere with the interpretation of the study results.

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting
• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting
• Henan Provincial People's Hospital
  Zhengzhou, Henan, China Recruiting
• Zhujiang Hospital of Southern Medical University
  Guangzhou, Guangdong, China Not yet recruiting
• The Third People's Hospital of Chengdu
  Chengdu, Sichuan, China Not yet recruiting

Study contacts

• Study coordinator: Yilong Wu, Prof. Dr. Med
• Email: gzyilong@hotmail.com
• Phone: 86-20-83821484

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.